i
This Document Has Been Replaced By: Update on recommendations for use of herpes zoster vaccine
Superseded
This Document Has Been Replaced By: Update on recommendations for use of herpes zoster vaccine
Update on herpes zoster vaccine: licensure for persons aged 50 through 59 years
-
November 11, 2011
Source: MMWR. Morbidity and mortality weekly report. 2011; 60(44):1528.
[HTM]
Details:
-
Alternative Title:MMWR. Morbidity and mortality weekly report
-
Description:Herpes zoster vaccine (Zostavax, Merck & Co., Inc.) was licensed and recommended in 2006 for prevention of herpes zoster among adults aged 60 years and older. In March 2011, the Food and Drug Administration (FDA) approved the use of Zostavax in adults aged 50 through 59 years. In June 2011, the Advisory Committee on Immunization Practices (ACIP) declined to recommend the vaccine for adults aged 50 through 59 years and reaffirmed its current recommendation that herpes zoster vaccine be routinely recommended for adults aged 60 years and older.
-
Subject:
-
Pubmed ID:22071592
-
Document Type:
-
Name as Subject:
-
Place as Subject:
-
Collection(s):
-
Main Document Checksum:
-
File Type:
Supporting Files
-
No Additional Files
More +
You May Also Like
[PDF - 70.38 KB]
[JPEG - 744.82 KB]
Email
CDC-INFO
